• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LOVASTATIN Drug Record

  • Summary
  • Interactions
  • Claims
  • LOVASTATIN chembl:CHEMBL503 ApprovedAntineoplastic

    Alternate Names:

    MEVINACOR 10
    SIMVASTATIN IMPURITY, LOVASTATIN-
    L-154803
    MEVINOLIN
    MEVACOR
    MEVINACOR
    MK-803
    ALTOPREV
    MEVINACOR 40
    LOVASTATIN
    C10AA02
    6-ALPHA-METHYLCOMPACTIN
    (1S,3R,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(2R,4R)-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL (S)-2-METHYL-BUTYRATE
    2Β,6Α-DIMETHYL-8ALPHA-(2-METHYL-1-OXOBUTOXY)-MEVINIC ACID LACTONE
    LOVASTATINA
    LOVASTATINUM
    6ALPHA-METHYLCOMPACTIN
    LOVASTATINE
    6Α-METHYLCOMPACTIN
    chemidplus:75330-75-5
    pubchem.compound:53232
    rxcui:6472
    drugbank:00227
    chembl:CHEMBL503

    Drug Info:

    Year of Approval 1987
    Drug Class anticholesteremic agents
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications anticholesterolaemic agent
    (5 More Sources)

    Publications:

    Pau et al., Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells., Biochem. Cell Biol.
    Arad et al., 1990, Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production., J. Lipid Res.
    Arad et al., 1992, Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins., Metab. Clin. Exp.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Yin OQ et al., 2012, Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects., Eur J Clin Pharmacol
    Buxbaum et al., 2001, Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide., J. Alzheimers Dis.
    Farina et al., 2002, Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells., Clin. Exp. Metastasis
    Podar et al., 2009, Emerging therapies for multiple myeloma., Expert Opin Emerg Drugs
    Baranova et al., 2002, [Concentration on Diapak C 16 capsules of lovastatin, mevinolinic acid and other inhibitors of biosynthesis of sterins produced by Penicillium citrinum 89]., Antibiot. Khimioter.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Abe et al., 2002, Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum., Mol. Genet. Genomics
    Miyazaki et al., 2002, Effects of pravastatin sodium on mevalonate metabolism in common marmosets., J. Biochem.
    Dimitroulakos et al., Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas., Neoplasia
    Zhou X et al., 2014, Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase., Bioorg Med Chem
    Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
    Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
    Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
    Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
    Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
    Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
    Iwama et al., 1995, Effect of lovastatin and fluoromevalonate on phosphatidylinositol 3-kinase activity stimulated with PDGF., Clin Exp Pharmacol Physiol Suppl
    Hung et al., 1999, Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol., J. Formos. Med. Assoc.
    Prasad et al., 2005, Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction., J. Neurochem.
    Kaneko R et al., 2007, Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer., J Biol Chem
    Ledoux et al., 2002, Lovastatin enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases., Circ. Res.
    Camarillo et al., 1997, Lovastatin inhibits prolactin-induced Nb2 cell mitogenesis and milk product synthesis in mouse mammary gland explants., Proc. Soc. Exp. Biol. Med.
    Medh et al., 1996, Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro., J. Biol. Chem.
    Rassoul et al., 2001, Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease., Int J Clin Pharmacol Ther
    Hubacek JA et al., 2009, Impact of apolipoprotein A5 variants on statin treatment efficacy., Pharmacogenomics
    Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
    Kim et al., 1999, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein., Pharm. Res.
    Hansen et al., 1995, Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia., Arterioscler. Thromb. Vasc. Biol.
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics
    Jiang et al., 1993, Transcriptional regulation by lovastatin and 25-hydroxycholesterol in HepG2 cells and molecular cloning and expression of the cDNA for the human hepatic squalene synthase., J. Biol. Chem.
    Hsu MH et al., 2007, Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin., J Biol Chem
    Tirkkonen et al., 2008, Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study., Drug Saf
    Ohno et al., 2007, General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs., Clin Pharmacokinet
    Riessen et al., 1999, Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells., Basic Res. Cardiol.
    Maddala et al., 2001, Lovastatin-induced cytoskeletal reorganization in lens epithelial cells: role of Rho GTPases., Invest. Ophthalmol. Vis. Sci.
    Esfahani et al., 1993, Effect of lovastatin on cell surface expression of Fc receptors or CD14 antigen in human monocytes., Biochem. Pharmacol.
    Tornio A et al., 2015, SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid., Pharmacogenet Genomics
    Hsiang B et al., 1999, A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters., J Biol Chem
    Lee et al., 1998, Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells., J. Biol. Chem.
    Kam et al., 1990, Effect of lovastatin on acyl-CoA: cholesterol O-acyltransferase (ACAT) activity and the basolateral-membrane secretion of newly synthesized lipids by CaCo-2 cells., Biochem. J.
  • LOVASTATIN   HMGCR

    Interaction Score: 1.66

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name lovastatin,Mevacor, Altocor, Altoprev
    Novel drug target Established target
    Mechanism of Interaction HMG-CoA reductase inhibitor

    PMIDs:
    12214063 12405293 19249983 12369143 11752352 12172803 12204108 12082550 24726306 17563401 18815589 18332269 16103896 18261733 15199031


    Sources:
    DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • LOVASTATIN   CD14

    Interaction Score: 1.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7506029


    Sources:
    NCI

  • LOVASTATIN   PXN

    Interaction Score: 1.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11581207


    Sources:
    NCI

  • LOVASTATIN   FDFT1

    Interaction Score: 1.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7685352


    Sources:
    NCI

  • LOVASTATIN   APOA5

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19530961


    Sources:
    PharmGKB

  • LOVASTATIN   SOAT1

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2268271


    Sources:
    NCI

  • LOVASTATIN   LIPA

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11380065


    Sources:
    NCI

  • LOVASTATIN   THBS1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10543307


    Sources:
    NCI

  • LOVASTATIN   CYP4F2

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17142457


    Sources:
    PharmGKB

  • LOVASTATIN   APOB

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7662319 2351867 1588827


    Sources:
    NCI

  • LOVASTATIN   TFPI

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7600119


    Sources:
    NCI

  • LOVASTATIN   CETP

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896


    Sources:
    PharmGKB

  • LOVASTATIN   NT5E

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11884371


    Sources:
    NCI

  • LOVASTATIN   LEP

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10083765


    Sources:
    NCI

  • LOVASTATIN   LPL

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8663292


    Sources:
    NCI

  • LOVASTATIN   SLCO1B1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26020121 16103896 10601278 15616150


    Sources:
    PharmGKB

  • LOVASTATIN   LDLR

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896


    Sources:
    PharmGKB

  • LOVASTATIN   UGT1A3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOVASTATIN   PRL

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9316617


    Sources:
    NCI

  • LOVASTATIN   SLCO2B1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOVASTATIN   SLCO1B3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOVASTATIN   UGT2B7

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOVASTATIN   CYP2C8

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOVASTATIN   PIK3CB

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9072409


    Sources:
    NCI

  • LOVASTATIN   PIK3CG

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9072409 15953363


    Sources:
    NCI

  • LOVASTATIN   CDK2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9553123


    Sources:
    NCI

  • LOVASTATIN   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978 15284534


    Sources:
    PharmGKB

  • LOVASTATIN   AKT1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17472962


    Sources:
    DTC

  • LOVASTATIN   UGT1A1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOVASTATIN   ABCC2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOVASTATIN   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15616150 10213372


    Sources:
    NCI PharmGKB

  • LOVASTATIN   RORC

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LOVASTATIN   NR1I2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOVASTATIN   SMN2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LOVASTATIN   SMN1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LOVASTATIN   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • LOVASTATIN   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 22281720


    Sources:
    DTC PharmGKB

  • LOVASTATIN   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 18302447 17655375


    Sources:
    DTC NCI PharmGKB

  • LOVASTATIN   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • LOVASTATIN   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • LOVASTATIN   IDH1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LOVASTATIN   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LOVASTATIN   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: LOVASTATIN

    • Version: 01-August-2011

    Alternate Names:
    LOVASTATIN Primary Drug Name

    Drug Info:
    Drug Class anticholesteremic agents
    Year of Approval 1987

    Publications:

  • TdgClinicalTrial: LOVASTATIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications anticholesterolaemic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: LOVASTATIN

    • Version: 14-September-2017

    Alternate Names:
    C620 NCI drug code

    Drug Info:

    Publications:
    Arad et al., 1990, Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production., J. Lipid Res.
    Pau et al., Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells., Biochem. Cell Biol.
    Arad et al., 1992, Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins., Metab. Clin. Exp.

  • DTC: LOVASTATIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL503 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Kaneko R et al., 2007, Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer., J Biol Chem
    Zhou X et al., 2014, Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase., Bioorg Med Chem

  • PharmGKB: lovastatin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics
    Yin OQ et al., 2012, Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects., Eur J Clin Pharmacol

  • TTD: Lovastatin

    • Version: 2020.06.01

    Alternate Names:
    D06WTZ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL503

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: LOVASTATIN

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL503

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21